First AD

Second AD

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Oncology Business Management

 Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

Advances in the Treatment of Prostate Cancer

Peer Exchange

Practical Advice on Follow-Up for Patients with M0 CRPC

Advancements in Nonmetastatic CRPC

Imaging Utilized in Diagnosis of CRPC

MFS as a Clinical Endpoint in nmCRPC

Benefits of Newly Approved Drugs for M0 CRPC

Management of Adverse Events in M0 CRPC

Cardiac Toxicity in Nonmetastatic CRPC

Expanding Treatment Options for Metastatic CSPC

ASCO 2019: Novel Agents in Metastatic CSPC

Historical Perspectives on ADT in Prostate Cancer

Frontline Therapy in Newly Diagnosed Metastatic HSPC

AR-V7 as a Predictive Biomarker in Metastatic CRPC

Reducing Risk of Fracture in Metastatic CRPC

Patient Selection for Radium-223 in mCRPC

Sequencing in Nonmetastatic and Metastatic CRPC

Considerations for Genetic Testing in Prostate Cancer

Role of PARP Inhibitors in Prostate Cancer